Taiwan Fund Seeks Shareholder Approval to Shift to Non-Diversified Investment Strategy
summarizeSummary
The Taiwan Fund filed a definitive proxy statement for its annual meeting, seeking shareholder approval to change its investment classification from diversified to non-diversified, which would allow for more concentrated portfolio holdings but also increase risk.
check_boxKey Events
-
Shareholder Meeting Scheduled
The Annual Meeting of Stockholders will be held on April 7, 2026, to vote on two proposals, including a significant change to the fund's investment strategy.
-
Proposed Investment Strategy Shift
Shareholders will vote on reclassifying the fund from a "diversified" to a "non-diversified" fund, a change recommended by the Board of Directors.
-
Increased Portfolio Concentration
If approved, the fund will no longer be subject to the 1940 Act's 5% single-stock exposure limit, enabling the adviser to take larger, more concentrated positions in fewer issuers.
-
Enhanced Risk Profile
The change to a non-diversified classification increases the fund's vulnerability to market changes affecting a limited number of holdings, as explicitly stated in the filing.
auto_awesomeAnalysis
This definitive proxy statement finalizes the details for a shareholder vote on a significant change to The Taiwan Fund's investment strategy, following a preliminary proxy filed on 2026-02-12. The core proposal is to reclassify the fund from "diversified" to "non-diversified" under the 1940 Act. This change would remove the 5% single-stock exposure limit, allowing the adviser to take more concentrated positions in high-conviction ideas. While the adviser believes this could enhance performance, it also explicitly increases the fund's risk profile by making it more vulnerable to adverse events affecting fewer, larger holdings. Investors should weigh the potential for enhanced returns against the increased concentration risk.
At the time of this filing, TWN was trading at $61.00 on NYSE in the Unknown sector, with a market capitalization of approximately $395.1M. The 52-week trading range was $26.45 to $64.25. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.